Adverum Biotechnologies Inc (ADVM)
$9.19
Insights on Adverum Biotechnologies Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 35.4%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 330.1%
Performance
- $9.14$10.10$9.19
0.54%
Downside
Day's Volatility :9.5%
Upside
9.01%
- $7.10$29.70$9.19
22.74%
Downside
52 Weeks Volatility :76.09%
Upside
69.06%
Returns
| Period | Adverum Biotechnologies Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -0.05% | 0.5% | 0.0% |
6 Months | -7.03% | 11.7% | 0.0% |
1 Year | 17.13% | 6.2% | 2.2% |
3 Years | -90.57% | 13.5% | -23.0% |
Highlights
Market Capitalization | 207.5M |
Book Value | $8.23 |
Earnings Per Share (EPS) | -11.6 |
PEG Ratio | 0.0 |
Wall Street Target Price | 40.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -3437.97% |
Return On Assets TTM | -32.14% |
Return On Equity TTM | -88.43% |
Revenue TTM | 3.6M |
Revenue Per Share TTM | 0.36 |
Quarterly Revenue Growth YOY | -70.0% |
Gross Profit TTM | -81.7M |
EBITDA | -118.1M |
Diluted Eps TTM | -11.6 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.41 |
EPS Estimate Next Year | -5.43 |
EPS Estimate Current Quarter | -0.34 |
EPS Estimate Next Quarter | -0.25 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 335.26%
Technicals Summary
Sell
Neutral
Buy
Adverum Biotechnologies Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Adverum Biotechnologies Inc | -33.64% | -7.03% | 17.13% | -90.57% | -86.05% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Adverum Biotechnologies Inc | NA | NA | 0.0 | -5.41 | -0.88 | -0.32 | NA | 8.23 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Adverum Biotechnologies Inc | Buy | $207.5M | -86.05% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
COMMODORE CAPITAL LP
4.82%Goldman Sachs Group Inc
4.39%VR Adviser, LLC
3.17%FMR Inc
2.95%Morgan Stanley - Brokerage Accounts
2.48%Versant Venture Management LLC
2.44%
Corporate Announcements
Adverum Biotechnologies Inc Earnings
Adverum Biotechnologies Inc’s price-to-earnings ratio stands at None
Read More
Company Information
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Organization | Adverum Biotechnologies Inc |
Employees | 121 |
CEO | Dr. Laurent Fischer |
Industry | Health Technology |
Discover More
Patrick Industries Inc.
$9.19
-2.13%
Moonlake Immunotherapeutics
$9.19
-2.13%
H&e Equipment Services Inc
$9.19
-2.13%
N-able Inc.
$9.19
-2.13%
Cerevel Therapeutics Holdings Inc
$9.19
-2.13%
Spdr Bloomberg Barclays Intermediate Term Corp Bond Etf
$9.19
-2.13%
Brunswick Corporation
$9.19
-2.13%
Banco Macro S.a.
$9.19
-2.13%
Brazil Capped Etf Msci Ishares
$9.19
-2.13%